Impact of Circulating N-Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients
Observational studyHumans
- Design
- Observational study
- Subjects
- Patients with end-stage renal disease on maintenance haemodialysis; number not stated in the abstract
- Dose used in the study
- Not applicable; palmitoylethanolamide was measured in serum, not given
- Duration
- 12-month follow-up for mortality
- What was measured
- Serum oleoylethanolamide and palmitoylethanolamide, correlations with clinical and laboratory indices, and association with 12-month all-cause mortality
What the authors reported
This observational study found:
- Both lipids correlated positively with HDL cholesterol and negatively with body fat and anthropometric measures.
- Oleoylethanolamide correlated with IL-6 (rho 0.19; p=0.004), and PEA showed a similar non-significant trend (rho 0.12; p=0.07).
- Serum PEA of 4.7 pmol/mL or higher was associated with higher mortality after adjustment (hazard ratio 2.99; 95% CI 1.04 to 8.64).
Limits of this study
An observational study of the body's own PEA levels in dialysis patients; it did not test PEA supplements and cannot show cause. The sample size is not stated in the abstract. Three authors are inventors on a related patent application filed by the University of California, Irvine.
Source
PubMed 33601382 · doi:10.1159/000513381
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.